
Bruck Kifle
Examiner (ID: 2018, Phone: (571)272-0668 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1622, 1624, 1202, 1611 |
| Total Applications | 3483 |
| Issued Applications | 2631 |
| Pending Applications | 211 |
| Abandoned Applications | 664 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17776519
[patent_doc_number] => 20220242868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => CO-CRYSTALS OF A BRUTON'S TYROSINE KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/471662
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471662
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/471662 | CO-CRYSTALS OF A BRUTON'S TYROSINE KINASE INHIBITOR | Sep 9, 2021 | Abandoned |
Array
(
[id] => 19060092
[patent_doc_number] => 11939300
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2
[patent_app_type] => utility
[patent_app_number] => 17/407565
[patent_app_country] => US
[patent_app_date] => 2021-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16600
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 223
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407565
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/407565 | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 | Aug 19, 2021 | Issued |
Array
(
[id] => 18770790
[patent_doc_number] => 20230365582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/042352
[patent_app_country] => US
[patent_app_date] => 2021-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44206
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042352
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/042352 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | Aug 19, 2021 | Pending |
Array
(
[id] => 18207181
[patent_doc_number] => 20230053437
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/785315
[patent_app_country] => US
[patent_app_date] => 2021-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41255
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -63
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785315
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/785315 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Aug 18, 2021 | Abandoned |
Array
(
[id] => 18657620
[patent_doc_number] => 20230303544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => LMO2 PROTEIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/021508
[patent_app_country] => US
[patent_app_date] => 2021-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021508
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/021508 | LMO2 PROTEIN INHIBITORS | Aug 17, 2021 | Pending |
Array
(
[id] => 17274395
[patent_doc_number] => 20210380593
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/404281
[patent_app_country] => US
[patent_app_date] => 2021-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 738
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17404281
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/404281 | PYRAZOLO-HETEROARYL DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | Aug 16, 2021 | Abandoned |
Array
(
[id] => 18770749
[patent_doc_number] => 20230365533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/040896
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44103
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040896
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/040896 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | Aug 15, 2021 | Pending |
Array
(
[id] => 17503370
[patent_doc_number] => 20220096472
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => PIPERIDINE-SUBSTITUTED MNK INHIBITORS AND METHODS RELATED THERETO
[patent_app_type] => utility
[patent_app_number] => 17/396187
[patent_app_country] => US
[patent_app_date] => 2021-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12843
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396187
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/396187 | Piperidine-substituted Mnk inhibitors and methods related thereto | Aug 5, 2021 | Issued |
Array
(
[id] => 17548103
[patent_doc_number] => 20220119444
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => Inhibitor of Apoptosis Protein (IAP) Antagonists
[patent_app_type] => utility
[patent_app_number] => 17/389171
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49832
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17389171
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/389171 | Inhibitor of apoptosis protein (IAP) antagonists | Jul 28, 2021 | Issued |
Array
(
[id] => 18108114
[patent_doc_number] => 20230000994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/387621
[patent_app_country] => US
[patent_app_date] => 2021-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 178544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 300
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387621
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/387621 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | Jul 27, 2021 | Issued |
Array
(
[id] => 17672647
[patent_doc_number] => 20220185814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/385269
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43111
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385269
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385269 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Jul 25, 2021 | Issued |
Array
(
[id] => 19210673
[patent_doc_number] => 11999721
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Pyrazole compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/384922
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 10497
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 559
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384922
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/384922 | Pyrazole compounds and uses thereof | Jul 25, 2021 | Issued |
Array
(
[id] => 18582835
[patent_doc_number] => 20230265090
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => QUINAZOLINE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 18/005347
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005347
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/005347 | Quinazoline compound | Jul 22, 2021 | Issued |
Array
(
[id] => 17426733
[patent_doc_number] => 20220054441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => COMPOSITIONS OF BETA-AMINOISOBUTYRIC ACID AND METHODS FOR USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/382476
[patent_app_country] => US
[patent_app_date] => 2021-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7597
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382476
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/382476 | Compositions of b-aminoisobutyric acid and methods for use thereof | Jul 21, 2021 | Issued |
Array
(
[id] => 18902660
[patent_doc_number] => 20240018145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA
[patent_app_type] => utility
[patent_app_number] => 18/015465
[patent_app_country] => US
[patent_app_date] => 2021-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37030
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015465
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/015465 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | Jul 21, 2021 | Pending |
Array
(
[id] => 18786051
[patent_doc_number] => 20230374017
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
[patent_app_type] => utility
[patent_app_number] => 18/017108
[patent_app_country] => US
[patent_app_date] => 2021-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26666
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017108
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017108 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | Jul 20, 2021 | Pending |
Array
(
[id] => 19097719
[patent_doc_number] => 20240116947
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/014775
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26107
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014775
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/014775 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Jul 13, 2021 | Abandoned |
Array
(
[id] => 18860120
[patent_doc_number] => 20230414554
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => COMPOUNDS FOR TREATING HEPATOCELLULAR CARCINOMA
[patent_app_type] => utility
[patent_app_number] => 18/016295
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016295
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016295 | COMPOUNDS FOR TREATING HEPATOCELLULAR CARCINOMA | Jul 13, 2021 | Pending |
Array
(
[id] => 17356735
[patent_doc_number] => 20220017531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => FLUORESCENT DYES
[patent_app_type] => utility
[patent_app_number] => 17/374514
[patent_app_country] => US
[patent_app_date] => 2021-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7900
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17374514
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/374514 | Fluorescent dyes | Jul 12, 2021 | Issued |
Array
(
[id] => 17355335
[patent_doc_number] => 20220016131
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => METHODS FOR IMPROVED TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/371750
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371750
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/371750 | Methods for improved treatment of cancer | Jul 8, 2021 | Issued |